Evaxion Biotech (NASDAQ:EVAX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.15) by 53.33 percent. This is a 99.56 percent increase over losses of $(16.00) per share from the same period last year. The company reported quarterly sales of $122.00 thousand which missed the analyst consensus estimate of $1.66 million by 92.65 percent. This is a 67.12 percent increase over sales of $73.00 thousand the same period last year.